Unicycive Therapeutics Inc Financials
This page shows Unicycive Therapeutics Inc (UNCY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing rather than meaningful revenue is carrying the business, while spending shifts are reshaping losses and liquidity.
Year over year, net loss narrowed by about$10.2M as R&D spending fell by about$10.9M . But operating cash burn still worsened to-$31.3M while SG&A reached$20.4M , showing the company shifted its cost mix rather than improving cash conversion.
The latest year looked more liquid on the surface: current ratio improved to 2.6x and debt-to-equity fell to 0.6x. But that repair came from financing inflows of
Free cash flow closely tracked operating cash flow, with only
Financial Health Signals
Unicycive Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Unicycive Therapeutics Inc passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Unicycive Therapeutics Inc reported a net loss of $26.6M while operations used $31.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Unicycive Therapeutics Inc reported an operating loss of $29.5M against $71K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Unicycive Therapeutics Inc's EBITDA was -$29.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 8.1% from the prior year.
Unicycive Therapeutics Inc reported -$26.6M in net income in fiscal year 2025. This represents an increase of 27.7% from the prior year.
Unicycive Therapeutics Inc earned -$1.67 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Unicycive Therapeutics Inc recorded an outflow of $31.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 9.4% from the prior year.
Unicycive Therapeutics Inc held $29.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Unicycive Therapeutics Inc's ROE was -87.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 406.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Unicycive Therapeutics Inc invested $9.1M in research and development in fiscal year 2025. This represents a decrease of 54.4% from the prior year.
Unicycive Therapeutics Inc invested $24K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 66.7% from the prior year.
Not reported for fiscal year 2025.
UNCY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $675K-29.0% | $951K | N/A | N/A |
| R&D Expenses | N/A | $9.1M-54.4% | $20.0M+55.1% | $12.9M+3.7% | $12.4M+104.5% | $6.1M+499.0% | $1.0M |
| SG&A Expenses | N/A | $20.4M+68.5% | $12.1M+41.6% | $8.5M+2131.6% | $383K+56.3% | $245K+322.4% | $58K |
| Operating Income | N/A | -$29.5M+8.1% | -$32.1M-54.6% | -$20.8M | N/A | -$9.0M | N/A |
| Interest Expense | N/A | $71K0.0% | $71K-13.4% | $82K+1266.7% | $6K-99.0% | $628K+157.4% | $244K |
| Net Income | N/A | -$26.6M+27.7% | -$36.7M-20.2% | -$30.5M | N/A | -$10.0M | N/A |
| EPS (Diluted) | — | -$1.67 | -$5.65 | -$1.28 | -$1.20-39.5% | -$0.86 | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
UNCY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $49.1M+55.2% | $31.7M+123.2% | $14.2M+403.6% | $2.8M-85.0% | $18.7M+9088.2% | $204K |
| Current Assets | $49.0M+58.2% | $30.9M+131.0% | $13.4M+406.8% | $2.6M-85.6% | $18.4M+8925.0% | $204K |
| Cash & Equivalents | $29.2M+11.7% | $26.1M+169.5% | $9.7M+2032.1% | $455K-97.3% | $16.6M | N/A |
| Inventory | N/A | N/A | N/A | $2.2M+19.5% | $1.8M | N/A |
| Total Liabilities | $18.9M-21.9% | $24.2M+34.6% | $18.0M+448.1% | $3.3M+45.3% | $2.3M-21.4% | $2.9M |
| Current Liabilities | $18.9M-21.5% | $24.1M+37.6% | $17.5M+433.9% | $3.3M+56.0% | $2.1M-26.8% | $2.9M |
| Total Equity | $30.2M+306.4% | $7.4M+295.1% | -$3.8M-717.4% | -$466K-102.8% | $16.5M+717.1% | -$2.7M |
| Retained Earnings | -$127.8M-26.2% | -$101.3M-56.9% | -$64.5M-89.8% | -$34.0M-113.3% | -$15.9M-169.1% | -$5.9M |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.
UNCY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$27.8M | -$31.3M-9.6% | -$28.6M-56.3% | -$18.3M | N/A | -$5.8M | N/A |
| Capital Expenditures | $9K | $24K-66.7% | $72K+500.0% | $12K+500.0% | $2K-93.1% | $29K | N/A |
| Free Cash Flow | -$27.9M | -$31.3M-9.4% | -$28.6M-56.6% | -$18.3M | N/A | -$5.8M | N/A |
| Investing Cash Flow | -$17.3M | -$12.1M-16698.6% | -$72K-500.0% | -$12K-500.0% | -$2K+93.1% | -$29K | N/A |
| Financing Cash Flow | $66.9M | $46.5M+3.1% | $45.1M+63.7% | $27.5M+5947.3% | -$471K-102.1% | $22.4M | N/A |
| Dividends Paid | N/A | N/A | $1.1M+21.7% | $900K | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
UNCY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | -3077.6% | N/A | N/A | N/A |
| Net Margin | N/A | N/A | -4525.0% | N/A | N/A | N/A |
| Return on Equity | -87.9%+406.3pp | -494.3% | N/A | N/A | -60.8% | N/A |
| Return on Assets | -54.0%+61.9pp | -116.0%+99.3pp | -215.2% | N/A | -53.4% | N/A |
| Current Ratio | 2.59+1.3x | 1.28+0.5x | 0.760.0x | 0.81-7.9x | 8.75+8.7x | 0.07 |
| Debt-to-Equity | 0.63-2.6x | 3.26 | N/A | N/A | 0.14 | N/A |
| FCF Margin | N/A | N/A | -2710.4% | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Unicycive Therapeutics Inc Ranks
Frequently Asked Questions
Is Unicycive Therapeutics Inc profitable?
No, Unicycive Therapeutics Inc (UNCY) reported a net income of -$26.6M in fiscal year 2025.
What is Unicycive Therapeutics Inc's EBITDA?
Unicycive Therapeutics Inc (UNCY) had EBITDA of -$29.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Unicycive Therapeutics Inc's return on equity (ROE)?
Unicycive Therapeutics Inc (UNCY) has a return on equity of -87.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Unicycive Therapeutics Inc's free cash flow?
Unicycive Therapeutics Inc (UNCY) recorded an outflow of $31.3M in free cash flow during fiscal year 2025. This represents a -9.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Unicycive Therapeutics Inc's operating cash flow?
Unicycive Therapeutics Inc (UNCY) recorded an outflow of $31.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Unicycive Therapeutics Inc's total assets?
Unicycive Therapeutics Inc (UNCY) had $49.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Unicycive Therapeutics Inc's capital expenditures?
Unicycive Therapeutics Inc (UNCY) invested $24K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Unicycive Therapeutics Inc spend on research and development?
Unicycive Therapeutics Inc (UNCY) invested $9.1M in research and development during fiscal year 2025.
What is Unicycive Therapeutics Inc's current ratio?
Unicycive Therapeutics Inc (UNCY) had a current ratio of 2.59 as of fiscal year 2025, which is generally considered healthy.
What is Unicycive Therapeutics Inc's debt-to-equity ratio?
Unicycive Therapeutics Inc (UNCY) had a debt-to-equity ratio of 0.63 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Unicycive Therapeutics Inc's return on assets (ROA)?
Unicycive Therapeutics Inc (UNCY) had a return on assets of -54.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Unicycive Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Unicycive Therapeutics Inc (UNCY) had $29.2M in cash against an annual operating cash burn of $31.3M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Unicycive Therapeutics Inc's Piotroski F-Score?
Unicycive Therapeutics Inc (UNCY) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Unicycive Therapeutics Inc's earnings high quality?
Unicycive Therapeutics Inc (UNCY) reported a net loss of $26.6M while operations used $31.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Unicycive Therapeutics Inc cover its interest payments?
Unicycive Therapeutics Inc (UNCY) reported an operating loss of $29.5M against $71K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.